Science Resources RSS Feeds
|
 |
 |
 |
Heparin Current Events | Heparin News
|
|
|
Sort By:
Page Views | Date |
Simple new method detects contaminants in life-saving drug
The blood-thinning drug heparin is highly effective when used to prevent and treat blood clots in veins, arteries and lungs, but earlier this year its reputation as a lifesaver was sullied when contaminated heparin products caused serious allergic reactions that led to a large number of deaths. view more (2008-11-18)
Less expensive anti-clotting medication appears as safe and effective as more expensive treatment
Subcutaneous (beneath the skin) injection of the original and less expensive form of the anticoagulant medication heparin is as effective and safe as subcutaneous administration of the newer and more expensive low-molecular-weight heparin for treatment of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs). view more (2006-08-23)
Patient safety advanced by revised heparin standards
Continuing to help ensure the identity, purity and quality of heparin, the U.S. Pharmacopeial (USP) Convention has revised written and physical standards for the widely used blood thinner. view more (2009-07-31)
Blood clots can be treated by injections at home
Treatment of blood clots in the deep veins of the legs or the lungs with an older, less expensive form of the anticoagulant medication heparin can be just as safe and effective as similar treatment with a newer and more expensive heparin. view more (2006-08-23)
Reduced Risk Of Recurrent Heart Attack With Anticoagulant Drug
Results of a study in this week's issue of THE LANCET show that patients given the anticoagulant drug, bivalirudin, had a reduced risk of recurrent heart attack compared with patients given conventional treatment with heparin. The combination of anticoagulant therapies (fibrinolytic therapy and the use of unfractionated heparin) for acute heart... view more... (2001-11-28)
UNC School of Pharmacy researchers create new synthetic heparin
Researchers at the University of North Carolina at Chapel Hill have patented a synthetic version of the drug heparin, called Recomparin, that is less complex chemically and should be easier to produce than previous forms. view more (2007-09-24)
Researchers create safer alternative to heparin
Robert Linhardt has spent years stitching together minuscule carbohydrates to build a more pure and safer alternative to the commonly used and controversial blood thinner heparin. view more (2008-08-18)
Deadly dose: Rensselaer heparin expert helps uncover source of lethal contamination
The mysterious death of patients around the world following a routine dosage of the common blood thinner, heparin, sent researchers on a frantic search to uncover what could make the standard drug so toxic. view more (2008-04-28)
'Artificial Golgi' may provide new insight into key cell structure
Scientists in New York and North Carolina are reporting assembly of the first functioning prototype of an artificial Golgi organelle. view more (2009-07-29)
Heparin antibodies may pose risk in heart surgery patients
New research suggests that patients who develop antibodies to the anti-clotting drug heparin nearly double their risk of death or serious complication after heart surgery. view more (2005-12-05)
Blood-compatible nanoscale materials possible using heparin
Researchers from Rensselaer Polytechnic Institute have engineered nanoscale materials that are blood compatible using heparin, an anticoagulant. The heparin biomaterials have potential for use as medical devices and in medical treatments such as kidney dialysis. view more (2006-05-08)
New Combination Therapy Could Reduce Ischaemia After Heart Attack (p 605)
Encouraging results from a fast-track study published in this week's issue of THE LANCET suggest a new therapeutic strategy for reducing ischaemic complications (coronary artery blockage) after heart attack. The treatment of acute heart attack requires combination of several therapies. Fibrinolytic agents given together with aspirin and... view more... (2001-08-22)
Mayo researchers explore reasons for complications with kidney failure patients
Mayo Clinic researchers searching for explanations of high mortality rates among kidney failure patients undergoing hemodialysis are focusing their attention on the use of heparin, a drug used to reduce clotting of the blood. view more (2005-08-18)
Chemists move closer toward developing safer, fully-synthetic form of heparin
Chemists are reporting a major advance toward developing a safer, fully-synthetic version of heparin, the widely used blood thinner now produced from pig intestines. The U. S. Food and Drug Administration last spring linked contaminated batches of the animal-based product, imported from China, to more than 80 deaths and hundreds of allergic... view more... (2008-08-18)
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes
Data from a phase II trial of an investigational intravenous drug designed to block the formation of blood clots shows potential to reduce the risk of death, a second heart attack, or other coronary complications compared with the current standard of care in patients presenting with acute coronary syndromes (heart attacks or unstable angina). view more (2009-08-31)
Heparin prepared synthetically could replace animal-derived drug
Researchers at Rensselaer Polytechnic Institute and University of North Carolina at Chapel Hill have discovered an alternative way to produce heparin, a drug commonly used to stop or prevent blood from clotting. view more (2006-02-07)
New treatment for severe malaria
The most dangerous form of malaria is difficult to treat and claims two million lives a year. Now, researchers at Karolinska Institutet in Sweden have developed a powerful new weapon against the disease. view more (2006-10-02)
Drug could change the standard treatment during procedures to clear blocked arteries
A study led by a University of Kentucky researcher being published in the country's leading medical journal could one day change the standard treatment for preventing blood clots during procedures to open up blocked arteries feeding the heart. view more (2006-09-11)
Findings released from 1 of the largest percutaneous coronary intervention trials ever
A study led by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center/NewYork-Presbyterian and chairman of the Cardiovascular Research Foundation, has shown that heart attack patients who were administered the direct thrombin inhibitor bivalirudin during primary angioplasty had a reduced rate of adverse clinical events,... view more... (2008-05-27)
MIT-led teams unravel heparin death mystery
An international team of researchers led by MIT has explained how contaminated batches of the blood-thinner heparin were able to slip past traditional safety screens and kill dozens of patients recently in the United States and Germany. view more (2008-04-24)
|
|
|
|
Sort By:
Page Views | Date |
|
|
